Last updated: 23 January 2018 at 11:31pm EST

Chris Storgard Net Worth




The estimated Net Worth of Chris Storgard is at least $146 Thousand dollars as of 23 November 2016. Chris Storgard owns over 37,593 units of Fate Therapeutics Inc stock worth over $145,861 and over the last 8 years Chris sold FATE stock worth over $0.

Chris Storgard FATE stock SEC Form 4 insiders trading

Chris has made over 1 trades of the Fate Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Chris bought 37,593 units of FATE stock worth $99,997 on 23 November 2016.

The largest trade Chris's ever made was buying 37,593 units of Fate Therapeutics Inc stock on 23 November 2016 worth over $99,997. On average, Chris trades about 9,398 units every 0 days since 2016. As of 23 November 2016 Chris still owns at least 37,593 units of Fate Therapeutics Inc stock.

You can see the complete history of Chris Storgard stock trades at the bottom of the page.



What's Chris Storgard's mailing address?

Chris's mailing address filed with the SEC is C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121.

Insiders trading at Fate Therapeutics Inc

Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part..., and Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.



What does Fate Therapeutics Inc do?

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.



What does Fate Therapeutics Inc's logo look like?

Fate Therapeutics Inc logo

Complete history of Chris Storgard stock trades at Fate Therapeutics Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
23 Nov 2016 Chris Storgard
Chief Medical Officer
Buy 37,593 $2.66 $99,997
23 Nov 2016
37,593


Fate Therapeutics Inc executives and stock owners

Fate Therapeutics Inc executives and other stock owners filed with the SEC include: